HLA-A and neoplasm: In one of the patients who achieved a CR after vaccination with HLA-A*02:01, ELISPOT assay showed an increased frequency of T cells secreting IFN-γ and IL-4 in PB in response to tumor-specific CDR1-, FR1-, and CDR3-derived peptides of a tumor-specific Ig heavy-chain sequences that were identified after the first vaccination.